Q3 EPS Forecast for Sangamo Therapeutics Boosted by Analyst

Key Points

• HC Wainwright has upgraded Sangamo Therapeutics' Q3 2025 earnings estimates to a projected $0.06 per share, a significant increase from their previous forecast of ($0.08).
• Despite the positive adjustment in forecast, overall sentiment is mixed with a consensus rating of "Hold" and an average target price of $4.50 on the stock.
• Sangamo Therapeutics reported a recent earnings miss with (0.08) EPS against an expected (0.07) EPS, and their last quarter revenue fell short at $18.31 million compared to a forecast of $31.68 million.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2025 earnings estimates for Sangamo Therapeutics in a research note issued on Tuesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of $0.06 for the quarter, up from their previous estimate of ($0.08). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.15 EPS.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, May 30th. Barclays cut their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.54 on Friday. Sangamo Therapeutics has a one year low of $0.41 and a one year high of $3.18. The company has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $0.71. The firm has a market capitalization of $125.91 million, a PE ratio of -1.86 and a beta of 1.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Sangamo Therapeutics by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company's stock valued at $1,263,000 after purchasing an additional 48,829 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $2,316,000. Schonfeld Strategic Advisors LLC bought a new stake in Sangamo Therapeutics in the 4th quarter worth about $1,744,000. Jacobs Levy Equity Management Inc. raised its position in Sangamo Therapeutics by 74.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock worth $851,000 after buying an additional 555,323 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Sangamo Therapeutics by 222.1% in the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock worth $1,033,000 after buying an additional 698,296 shares during the last quarter. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.